Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Health Technology Assessment Market Access Policy

German HTA Negative On Benefits Of First Ever Peanut Allergy Treatment

  • News

Executive Summary

The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.

You may also be interested in...



England’s NICE Okays First Ever Peanut Allergy Treatment Palforzia

Aimmune Therapeutics secures agreement with NHS for “step change” in treating peanut allergy.

Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion

Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.

UK ABPI Suspends Novo Nordisk Over Code Breach

Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.

Table

View full table

Topics

Related Companies

Tags:
Health Technology Assessment Market Access Policy
Latest Headlines

Australia To Seek Stakeholder Input On Terms Of HTA Review

A Milestone Moment For Pharmacogenomics: US FDA Ready To Drop ‘Voluntary’ Program

Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations

Device Component Of Intarcia’s Diabetes Treatment ITCA 650 Worries FDA

See All
UsernamePublicRestriction

Register

PS145594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By